Physician profile
Breanna E Caro
NPI 1992028476
$4,330.02
in general payments reported to CMS, 2019-2025
32 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,021 · 2022: $891 · 2023: $818 · 2024: $1,079 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,392 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,392.21 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $665.63 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $568.42 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $493.50 | 2022-2025 | |
| Currax Pharmaceuticals LLC | $345.60 | 2023-2025 | Contrave, Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $255.33 | 2024-2025 | Spravato |
| Impulse Dynamics (USA) INC. | $221.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.39 | 2021 | |
| Novo Nordisk INC | $181.12 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $179.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $148.67 | 2024-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.35 | 2021-2025 | Jardiance |
| Pfizer INC. | $112.51 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.73 | 2021-2022 | |
| Atricure, INC. | $85.00 | 2024 | |
| Merck Sharp & Dohme LLC | $84.49 | 2021-2024 | Gardasil 9, M-M-R II, Capvaxive |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $68.59 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $64.19 | 2021-2022 | |
| Glaxosmithkline, LLC. | $60.43 | 2021-2024 | Arexvy, Shingrix |
| Medtronic, INC. | $56.42 | 2022-2023 | Linq II |
| Horizon Therapeutics Plc | $41.35 | 2021-2022 | |
| Phadia US INC. | $36.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $34.85 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $23.65 | 2025 | |
| Exeltis, USA INC. | $23.40 | 2023 | Slynd |
| Ultragenyx Pharmaceutical INC. | $23.29 | 2023 | |
| Bausch Health US, LLC | $21.39 | 2021 | |
| Upsher-Smith Laboratories LLC | $20.94 | 2021 | |
| Abiomed | $18.34 | 2024 | Impella |
| Exact Sciences Corporation | $18.27 | 2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $15.88 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.29 | 2022 | |
| Itamar Medical INC | $14.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breanna Caro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.